Neomatrix: An Innovative, Fully-Synthetic DNA Platform for Next Generation Cancer Vaccines
Time: 2:00 pm
day: Day Two
Details:
- Evaluating how neoantigen identification is key for the design of personalised cancer vaccines and the requirements of prediction algorithm
- Enhancing a fast and reliable manufacturing technology and how synthetic DNA allowed the production of NCV in few days, without complex upstream and downstream procedures
- Investigating a efficient delivery method by using Electroporation which enhances gene expression and acts as adjuvant of immune response
